MediciNova (MNOV) Expected to Announce Quarterly Earnings on Wednesday

MediciNova (NASDAQ:MNOV) will likely be posting its results before the market opens on Wednesday, November 12th. Analysts expect MediciNova to post earnings of ($0.08) per share for the quarter.

MediciNova (NASDAQ:MNOV) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $0.14 million for the quarter. On average, analysts expect MediciNova to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MediciNova Price Performance

Shares of MNOV opened at $1.42 on Monday. The firm has a market capitalization of $69.65 million, a P/E ratio of -5.68 and a beta of 0.50. MediciNova has a one year low of $1.13 and a one year high of $2.55. The business has a fifty day moving average of $1.28 and a 200 day moving average of $1.33.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediciNova in a research report on Wednesday. Zacks Research raised shares of MediciNova to a “hold” rating in a report on Thursday, September 11th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of MediciNova in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.